Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia
- 1 September 1995
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 10 (3) , 127-138
- https://doi.org/10.2165/00044011-199510030-00001
Abstract
The clinical efficacy and tolerability of simvastatin and fluvastatin were compared in 432 patients with primary hypercholesterolaemia in a multinational, randomised, double-blind trial. Following at least 10 weeks on a lipid-lowering diet, patients continuing to have a total cholesterol level ≥ 6.5 mmol/L and elevated low density lipoprotein (LDL) cholesterol levels received 6 weeks of once-daily treatment with either simvastatin 5mg (n = 109), simvastatin 10mg (n =110), fluvastatin 20mg (n = 105), or fluvastatin 40mg (n = 108). The relative potency rates of simvastatin to fluvastatin in reducing LDL and total cholesterol levels were estimated to be 7.60 and 7.65, respectively. Significantly greater mean reductions in LDL cholesterol levels were found at week 6 with simvastatin 10mg (30%) compared with either fluvastatin 20mg (22%; p < 0.001) or fluvastatin 40mg (26%; p = 0.03). Similarly, LDL cholesterol was lowered more in the simvastatin 5mg group (26%) than in the fluvastatin 20mg group (22%; p = 0.03). No significant difference was seen between simvastatin 5mg and fluvastatin 40mg. Plasma total cholesterol levels were also significantly lower with simvastatin 10mg compared with fluvastatin 20mg (23 vs 16%; p < 0.001) and fluvastatin 40mg (23 vs 19%; p = 0.02), and with simvastatin 5mg compared with fluvastatin 20mg (19 vs 16%; p = 0.01). Simvastatin 5mg and fluvastatin 40mg both lowered total cholesterol levels by 19%. The percentage of patients reaching National Cholesterol Education Program Adult Treatment Panel II (NCEP ATP II) target LDL cholesterol levels after 6 weeks’ treatment with simvastatin 5 or 10 mg/day or fluvastatin 20 or 40 mg/day was 24, 25, 12 and 21%, respectively. Tolerability profiles were generally similar, although significantly more gastrointestinal adverse events occurred in the fluvastatin-treated patients (23 vs 11%). In conclusion, simvastatin 10 mg/day is more effective in lowering total and LDL cholesterol levels than the maximum recommended dose of fluvastatin (40 mg/day), whereas simvastatin 5 mg/day and fluvastatin 40 mg/day showed similar efficacy.Keywords
This publication has 14 references indexed in Scilit:
- Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)The Lancet, 1994
- Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-IThe American Journal of Medicine, 1994
- Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramineEuropean Journal of Clinical Pharmacology, 1994
- Clinical implications of the biopharmaceutical properties of fluvastatinThe American Journal of Cardiology, 1994
- Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA studyBMJ, 1994
- Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)1993
- A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.1993
- Cholesterol lowering and the reduction of CHD incidence and total mortality: Results from a meta-analysis of randomized trialsCardiovascular Drugs and Therapy, 1992
- Cholesterol and mortality. 30 years of follow-up from the Framingham studyJAMA, 1987
- Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative UltracentrifugeClinical Chemistry, 1972